Axel Hyrenius-Wittsten和同事以相似的方式设计了带有可识别ALPPL2受体的synNotch-CAR T细胞；ALPPL2是出现于诸如间皮瘤等实体瘤上的特异性蛋白。

本研究开发了一种新型的基于synNotch平台的抗HIV-1合成T细胞疗法，为艾滋病（AIDS）的功能性治愈提供了新思路。 在抗逆转录病毒治疗（ART）下，HIV-1感染者的病毒载量可被抑制至几乎无法检测的水平，但无法根除HIV感染，原因在于病毒在感染细胞中存在巨大的 ...

(1) A chimeric antigen receptor (CAR) is a modular, synthetic receptor that endows T cells with different targeting abilities. Several emerging engineering approaches aim to improve the safety, ...

Chimeric antigen receptor T cells, better known as CAR T cells, are powerful immunotherapy agents derived from a cancer patient’s existing immune cells and engineered to fight their specific tumors.

California biotech Calibr and partner AbbVie have reported the first clinical data on a new CAR-T technology, which uses "switchable" cells that aim to eliminate the life-threatening side-effects ...

Researchers have successfully developed a supercharged iteration of CAR-T cell therapy that can enhance the effectiveness and longevity of the cells, particularly against cancer cells that are ...

As interest in immunotherapy grows, so does the need for better tools to engineer CAR T cells. Could advances in CRISPR technology be the solution? In the last decade, a new immunotherapy tool has ...

Researchers at the University of Colorado Anschutz Medical Campus have successfully developed a supercharged iteration of CAR-T cell therapy that can enhance the effectiveness and longevity of the ...

Using a multipronged strategy, Celyad is driving the development of next-generation chimeric antigen receptor-T cell-based therapies to treat cancer. Lead programs include both autologous and ...